OBJECTIVES: To investigate the global perspectives of Turkish Rheumatologists regarding expected FMF prevalence, undiagnosed patients ratio, arguments in diagnostic procedure and management of FMF. METHODS: A questionnaire consist of estimated frequency, diagnostic modalities and follow up characteristics in addition to therapeutic approach was set up. Even though a regular colchicine use, ≥1 attack /month during 6 months was accepted as colchicine resistant. All members of Turkey Society for Rheumatology from country wide (n=235) were invited to fill in the web-based questionnaire for FMF by e-mail. Totally 108 members (45.9%) answered the questionnaire. RESULTS: Estimated prevalence was median 0.2% (IQR25-75: 0.1-0.7) for FMF. Only 51.4±19.0 % of these patients had been diagnosed according to Rheumatologists opinion. Time to diagnosis from the first symptom was more than 3 years in 49.5% of patients. Description of typical attacks in anamnesis is the most frequent parameter in diagnosis of patients whereas in 26.7 %of patients MEFV mutations were required for diagnosis.